RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Homology Medicines Stock

Homology Medicines Stocks 2024

Homology Medicines Stocks

3.21 M

Ticker

QTTB

ISIN

US4380831077

WKN

A2JGTY

In 2024, Homology Medicines had 3.21 M outstanding stocks, a 0% change from the 3.21 M stocks in the previous year.

The Homology Medicines Stocks history

YEARNUMBER OF STOCKS (undefined USD)
2026e3.21
2025e3.21
2024e3.21
20233.21
202257.4
202155.28
202045.91
201942.12
201828.55
201733.75
201636.08

Homology Medicines shares outstanding

The number of shares was Homology Medicines in 2023 — This indicates how many shares 3.213 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Homology Medicines earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Homology Medicines's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Homology Medicines’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Homology Medicines's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Homology Medicines Aktienanalyse

What does Homology Medicines do?

Homology Medicines Inc. is a US-based company focused on the development of gene therapy technologies. The company was founded in 2015 and is headquartered in Bedford, Massachusetts. Homology Medicines Inc. aims to develop and market innovative gene therapies for rare diseases and genetic disorders. The company's goal is to develop new therapies through gene editing that can specifically modify genes to treat or alleviate symptoms of diseases. Homology Medicines bases its methodology on the natural processes of viral transport, through which double-stranded DNA is anchored into the cell. This allows the DNA to be directly introduced into living tissue, where it has systemic effects. Homology's gene therapy technology is based on the recombination of adenoviral vectors. The business model of Homology Medicines is to develop and market innovative gene therapies for rare diseases and genetic disorders. The company focuses on close collaboration with clinics to make the new therapies quickly and efficiently available to patients. The company has a close partnership with the National Institute of Health (NIH) to utilize its technology for gene therapy of rare diseases and genetic disorders. Homology Medicines Inc. specializes in three different branches of gene therapy: 1. In vivo gene therapy: In this method, gene therapies are directly introduced into the patient's tissue. Homology Medicines is working on developing new efficient methods for virus transport of therapeutics into the central nervous system and cardiovascular tissue. These methods aim to minimize the occurrence of unwanted effects. 2. Ex vivo gene therapy: In ex vivo gene therapy, a patient's cells are taken, modified, and then reintroduced into the patient. This method is particularly relevant for immune system disorders and cancer treatments. Homology Medicines is working on new efficient methods for the transport of modifiers into cells. 3. Genome editing therapy: In this final branch, Homology Medicines is working on developing genome editors that are specifically designed for defective genes. The technology is intended for the treatment of genetic diseases and restoring the functionality of defective genes. Homology Medicines Inc. is known for its low costs in gene therapy development. By utilizing natural viral transport methods and closely analyzing defects in humans, the company is able to quickly and cost-effectively develop therapies for patients. The company has already initiated several successful developments in gene therapy and continues to seek new innovations and developments to better meet the needs of patients. Homology Medicines ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating Homology Medicines's Shares Outstanding

Homology Medicines's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in Homology Medicines’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding Homology Medicines’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in Homology Medicines’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about Homology Medicines stock

How many stocks are there of Homology Medicines?

The current number of stocks of Homology Medicines is 3.21 M undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of Homology Medicines are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of Homology Medicines evolved in recent years?

The number of shares of Homology Medicines has increased by 0% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. Homology Medicines as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of Homology Medicines?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does Homology Medicines pay?

Over the past 12 months, Homology Medicines paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Homology Medicines is expected to pay a dividend of 0 USD.

What is the dividend yield of Homology Medicines?

The current dividend yield of Homology Medicines is .

When does Homology Medicines pay dividends?

Homology Medicines pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Homology Medicines?

Homology Medicines paid dividends every year for the past 0 years.

What is the dividend of Homology Medicines?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Homology Medicines located?

Homology Medicines is assigned to the 'Health' sector.

Wann musste ich die Aktien von Homology Medicines kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Homology Medicines from 7/12/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/12/2024.

When did Homology Medicines pay the last dividend?

The last dividend was paid out on 7/12/2024.

What was the dividend of Homology Medicines in the year 2023?

In the year 2023, Homology Medicines distributed 0 USD as dividends.

In which currency does Homology Medicines pay out the dividend?

The dividends of Homology Medicines are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Homology Medicines

Our stock analysis for Homology Medicines Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Homology Medicines Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.